Welcome to our dedicated page for Newhydrogen SEC filings (Ticker: NEWH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page is intended to provide access to NewHydrogen, Inc. (NEWH) regulatory filings and related disclosures as they become available. While no SEC filings are listed in the provided data, investors commonly look to this section for documents that explain how a company like NewHydrogen describes its ThermoLoop™ thermochemical water-splitting technology, its research collaboration with the University of California, Santa Barbara, and its plans for development and commercialization of clean or green hydrogen production.
For a company focused on hydrogen technology, annual reports (Form 10-K) and quarterly reports (Form 10-Q), when filed, can contain narrative and risk-factor discussions about technology development, intellectual property such as patents, research agreements, and the company’s view of the clean or green hydrogen market. They may also describe how management evaluates milestones such as lab demonstrations, pilot-scale planning, and integration studies with power plants or other heat sources.
Event-driven filings such as Form 8-K, when present, can provide additional detail on matters the company deems material, which could include new patent filings, significant research developments, or changes in technical leadership related to ThermoLoop. Ownership-related filings such as Form 4, if available, can show transactions in NewHydrogen securities by directors, officers, or other insiders.
On Stock Titan, NEWH filings are accompanied by AI-powered summaries designed to highlight key points from lengthy documents, such as descriptions of ThermoLoop technology, references to UC Santa Barbara collaboration, or discussions of heat sources like power plants and Small Modular Reactors that the company identifies in its public communications. These summaries aim to make it easier to understand the main themes of each filing without reading every page.
As NewHydrogen submits filings to the SEC’s EDGAR system, this page can be used to review those documents in one place, compare disclosures over time, and see how the company’s formal regulatory language aligns with the technology and development narratives described in its news releases.
NewHydrogen, Inc. is a development-stage clean energy company focused on ThermoLoop™, a thermochemical process that uses heat and water to produce low-cost green hydrogen. The company reported no revenue in 2025 and a net loss of $2.85 million, driven mainly by higher general and administrative, research and development, and marketing expenses.
Cash at year-end 2025 was $1.44 million with working capital of $1.43 million, and the firm expects existing cash to fund operations for about six months, anticipating additional capital needs in the second half of 2026. Accumulated deficit reached $180.79 million, and the auditor’s report and management both note substantial doubt about the company’s ability to continue as a going concern.
NewHydrogen has two full-time employees, 768,031,041 common shares outstanding as of March 30, 2026, and an estimated non-affiliate market value of $22.42 million. The business is pre-commercial, with no backlog or government contracts, and relies on university research partnerships and equity financing to advance its hydrogen technology.
NewHydrogen, Inc. reported Q3 2025 results with no revenue and a wider year‑to‑date loss. Net loss was $1,581,894 for the nine months ended September 30, 2025, including a Q3 loss of $482,096. Operating expenses totaled $1,582,324 year to date, driven by higher general and administrative, research and development, and selling and marketing spending.
Cash was $1,306,271 at September 30, 2025, down from $2,104,521 at year‑end, after $1,413,695 used in operations. The company raised $615,445 via its equity financing agreement with GHS, issuing 25,245,680 shares and 803,536 shares for a $30,000 commitment fee. Shareholders’ equity (deficit) was $(2,111,010), and accumulated deficit reached $179,524,441. Working capital was $1,318,162. Management references going‑concern uncertainty but believes current resources support about nine months of operations. As of November 10, 2025, common shares outstanding were 759,218,392. Subsequent to quarter‑end, additional shares were issued to GHS under the financing agreement.